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[571 ABSTRACT 
A method for the alleviation of both motion sickness 
and chemically-induced emesis is provided which in- 
cludes the administration of a nontoxic, therapeutically 
effective amount of a composition which stimulates 
serotonin-1A receptors in a mammal in need of such 
treatment. The preferred compounds for use are buspi- 
rone and 8-hydroxy-2(di-n-propylamino)-tetralin (8- 
OH-DPAT). 
13 Claims, 2 Drawing Sheets 
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1 
STIMULATION OF SEROTONIN-1A RECEPTORS 
IN MAMMALS TO ALLEVIATE MOTION 
SICKNESS AND EMESIS INDUCED BY 
CHEMICAL AGENTS 
BACKGROUND OF THE INVENTION 
The invention described herein was made in the per- 
formance of work under NASA Contract NCC-2-229 
and is subject to the provisions of 35 U.S.C. sections 200 
et seq. 
CATIONS 
This application is a continuation-in-part of U.S. pa- 
tent application Ser. No. 071,896, filed July 10, 1987. 
This invention relates to a method of alleviating both 
motion sickness and emesis induced by chemical agents, 
and more particularly to the use of compositions which 
stimulate serotonin-1A receptors in mammals to 
achieve this purpose. 
There are currently no known strategies or agents 
which are effective in blocking emesis caused from a 
variety of different stimuli. While some agents are effec- 
tive in blocking emesis from one stimulus, the same 
agent may be ineffective against emesis elicited from 
another stimulus. For example, agents which are known 
to be effective in blocking motion sickness have not 
been found to be effective against emesis which is in- 
duced chemically. Moreover, even agents having such 
CROSS-REFERENCE TO RELATED APPLI- 
exhibit the sedative effects of presently used agents. It 
would also be desirable to find a drug or class of drugs 
which are also effective in blocking chemically induced 
emesis from a variety of stimuli. Accordingly, there is 
still a need in the art for a drug or class of drugs which 
will alleviate or block motion sickness and/or chemi- 
cally induced emesis but which do not exhibit sedative 
effects on the patient. 
10 SUMMARY OF THE INVENTION 
The present invention meets that need by providing a 
class of agents for the alleviation of motion sickness as 
well as chemically induced emesis in mammals which 
15 do not have the sedative side effects of other agents 
presently in use. In accordance with one aspect of the 
present invention, a mammal in need of treatment for 
motion sickness or chemically induced emesis is admin- 
istered a nontoxic, therapeutically effective amount of a 
2o composition which stimulates serotonin- 1A receptors in 
a mammal in need of such treatment. Examples of pre- 
ferred serotonin- 1A stimulators include 8-hydroxy-2(di- 
n-propy1amino)-tetralin, also known as 8-OH-DPAT, 
25 and buspirone. An anticipated preferred dose is approxi- 
mately 0.002 to about 4.0 mg/kg of body weight, with 
dosage being dependent upon a number of factors in- 
cluding the species of mammal, the mammal’s suscepti- 
bility to emetic stimuli, and the nature of the stimulus. 
The preferred serotonin- 1A stimulating compounds 30 limited effectiveness such as antihistamines and an- 
timwarinics may produce undesjrable sedative side are from two different drug classes and appear to share 
effects. the effect of stimulating serotonin-1A receptors in a 
This ineffectiveness of known antiemetic agents mammal to block both motion and chemically induced 
against a variety of stimuli is believed to be due to the emesis. Because different stimuli induce emesis through 
fact that workers in the art have determined that differ- 35 different neural pathways, applicants believe that the 
ent neural Pathways are resPmible for chemically- site of the serotonin-1A receptors must be at a conver- 
induced vomiting than for motion-induced emesis. See, gent structure in the brain, presumably at or very near 
xylazine stimulates alpha-2 noradrenergic receptors in 40 responses that constitutes the emetic sequence. While 
both of the preferred serotonin-1A stimulating agents the area postrema, also known as the chemical trigger zone, in the brain. Cisplatin, a cytotoxic drug com- 
pound used in cancer chemotherapy, triggers emetic also exhibit antianxiety action, other well-known anti- 
effects by activating nerves passing though or close to anxiety agents have not been found to possess this 
the area postrema. 
Ablation of the area postrema eliminates emesis elic- object Of the present invention 
ited by xylazine and cisplatin compounds. See, Colby et to provide a method for the alleviation of motion sick- 
al, “Emetic Action of Xylazine on the Chemoreceptor ness and/or chemically induced emesis in a mammal in 
Trigger Zone for Vomiting in Cats”, 4 J. Vet. Phar- need of treatment by the administration of an agent 
macol. Therap. 9396 (1981) and McCarthy and Borison, 50 which does not have the sedative effects of other previ- 
“Cisplatin-induced Vomiting E l i i a t e d  by Ablation of ously used agents. This, and other objects and advan- 
the Area Postrema in Cats”, 68 Cancer Treat. Rep. tages of the invention will become apparent from the 
401-404 (1984). The mechanism for motion-ind~ed following detailed description, the accompanying 
emesis, however, uses a neural pathway that does not drawing figures, and the appended 
require the area postrema Ablation of the area post- 55 
rema does not eliminate motion-induced emesis. Bori- 
son and “Motion sickness Reflex Arc By- 
Brand and Perry, ‘‘Drugs Used In Motion Sickness”, 18 
Pharmacol’ Rev* 895-924 (1966). For the drug 
the somewhat fil-defmed vomiting center. This center is 
believed to program the complex series of reflexive 
45 broad-spectrumed antiemetic effect. 
Accordingly, it iS 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 graphically illustrates the dosage dependent 
ministration of buspirone. Control tests following saline 
treatment alone were made both before (Vl) and after induced emesis, it does not block motion sickness. 
Lucot and Crampton, ssXylazine Emesis, Yohimbine, (V2) the determination of the dose response function; 
and Motion Sickness Susceptibility in the Cat”, 237 and 
Phmacol.  Exp. Therap. 450-455 (1986). Also, while FIG. 2 graphically illustrates the dosage dependent 
the drug scopolamine blocks motion sickness, it does 65 reduction Of both motion sickness (solid circles) and 
not prevent xylazine-induced emesis. xylazine-induced emesis (open circles) in ten cats by the 
It would be desirable to find a drug or class of drugs administration of 8-hydroxy-2(di-n-propylamino)-tetra- 
which effectively alleviate motion sickness but do not lin. The log of the dose of 8-OH-DPAT is presented. 
Passes the Area postrema in Cats”, 92 Exp’ 
723-737 (1986). reduction of motion sickness in twenty cats by the ad- 
Similarly, while the drug yohimbine blocks xylazine- 60 
4,943,428 
DESCRIPTION OF THE PREFERRED 
EMBODIMENTS 
The process of the present invention utilizes a class of 
compositions which act as stimulators for serotonin-1A 
sites in the brains of mammals. These sites are believed 
to be at or near the vomiting center in the brain stem, 
the point at which the complex series of reflexive re- 
sponses constituting the emetic sequence is pro- 
grammed. The activity of this class of compositions, at 
the convergent vomiting center, makes them useful in 
treating and alleviating emetic responses to a wide vari- 
ety of emetic stimuli, including both motion and chemi- 
cal sources. 
In this art, cats are recognized as suitable test animals 
with test results being correlatable with utility in hu- 
mans. Like humans, some cats are more susceptible to 
motion sickness than others. The cerebrospinal fluid of 
cats that had become motion sick was studied. It was 
determined that the cerebrospinal fluid of those cats had 
lower baseline levels of 5-hydroxyindolacetic acid than 
the fluid of cats not becoming motion sick. Accord- 
ingly, it would appear that nerves using serotonin as a 
transmitter substance may be involved in the emetic 
process. Applicants believe that this lower activity in 
serotogenic systems of cats which are more susceptible 
permits motion sickness and possibly other emetic syn- 
dromes to develop. 
4 
5. Wu et al., U.S. Pat. No. 3,976,776, issued Aug. 24, 
1976, entitled “Tranquilizer Process Employing N- 
(Heteroarcyc1ic)piperazinylalkylazaspiroalkaned- 
iones”. 
In recent years, buspirone has found use in a number 
of different clinical methods. For example, Casten et al., 
U.S. Pat. No. 4,182,763, issued Jan. 8, 1980, teaches that 
buspirone is useful as an anti-anxiety agent in the treat- 
ment of psychiatric disorders. Kurtz et al., U.S. Pat. No. 
10 4,634,703, issued Jan. 6, 1987, teaches that buspirone is 
useful in the treatment of panic disorders. 
Allen et al., U.S. Pat. No. 4,438,119, issued Mar. 20, 
1984, teaches that buspirone alleviates extrapyramidal 
motor disorders such as Parkinson’s disease. Finally, 
15 Othmer et al., U.S. Pat. No. 4,640,921, issued Feb. 3, 
1987, teaches that buspirone may be used to treat sexual 
dysfunction. While buspirone has found an increasing 
number of uses in recent years, to applicants’ knowl- 
edge, it has never been used to attempt to alleviate 
Buspirone is known to be a partial agonist at 5- 
hydroxytryptaminelA receptors, where it binds with 
sixteen times greater a f f i t y  than at dopamine recep- 
tors. Buspirone preferentially antagonizes presynaptic 
25 dopamine;! receptors, so that it not only mimics 5- 
hydroxytryptamine transmission, but also, at higher 
5 
20 motion sickness in mammals. 
doses, increases dopaminergenic transmission. See, An- 
drade and Nicoll, “The Novel Anxiolytic Buspirone 
Elicits a Small Hyperpolarization and Reduces Seroto- The preferred iomwunds for use in the Dractice of ~~ 
the prkess of the present invention are kndwn. While 
they are from different chemical classes, they share the 
common property of stimulating serotonin-1A recep- 
tors. One of the preferred compounds is the pyrimidine 
compound, better known as buspirone, or a pharmaceu- 
tically acceptable acid addition salt thereof. Buspirone 
has the following structural formula: 
0 
The hydrochloride salt has been referred to in the 
prior art as MJ 9022-1 and as buspirone hydrochloride. 
Other acid addition salts thereof are named by combin- 
ing “buspirone” with the appropriate word to define the 
acid from which it is prepared as in “buspirone hydro- 
chloride”. The latter is the United States Adopted 
Name (USAN). See, 225 J. Amer. Med. Assn. 520 
(1973). 
The synthesis of the compound and the identification 
of its properties are described in the following patents 
and publications: 
1. Wu et al., 15 J. Med. Chem. 477 (1972). “Psy- 
chosedative Agents. 2. 8-(4Substituted 1- 
piperazinylalkyl)-8-azaspiro[4.5]decane-7,9-diones”; 
2. Wu et al., U.S. Pat. No. 3,717,634, issued Feb. 20, 
1973, entitled “N-(Heteroarcyc1ic)piperazinylalkylazas- 
piroalkanediones”; 
3. Allen et al., Arzneim.-Forsch. 24, Nr. 6, 
917-22(1974). “Pharmacologic Effects of MJ 9022-1, a 
Potential Tranquilizing Agent”; 
4. Sathananthan et al., 18 Therapeutic Research 
701-O5( 1975). “MJ 9022: Correlation Between Neuro- 
leptic Potential and Stereotypy”; and 
30 nin Responses on Hippocampal CAI pyramidal Cells”, 
SOC. Neurosci. Abstr. 11, 597 (1985); McMillan, Mat- 
thews, Sanghera, Shepard and German, “Dopamine 
Receptor Antagonism by the Novel Antianxiety Drug, 
Buspirone”, J. Neurosci. 3, 733-738 (1983): and Pe- 
35 routka, “Selective Interaction of Novel Anxiolytics 
with 5-Hydroxytryptamine-1A Receptors”, Biol. Psy- 
chiat. 20,971-979 (1985). As buspirone acts to stimulate 
a subtype of serotonin receptor known as the serotonin- 
1A site, applicants have found that the use of buspirone 
40 in this manner in mammals having a susceptibility to 
motion sickness counteracts the lower serotogenic and- 
/or dopaminergenic activities and blocks or otherwise 
alleviates the symptoms of motion sickness. 
Further, applicants have also found that buspirone is 
45 effective in blocking chemically-induced emesis in cats, 
the chemical xylazine is a known agent which induces 
emesis. Treatment with buspirone prior to exposure to 
xylazine acts to block the action of that chemical agent. 
While the exact mechanism by which buspirone blocks 
50 emesis is not known, applicants believe that buspirone 
acts at the convergent vomiting center in its stimulation 
of serotonin-1A receptor sites. This conclusion is par- 
tially based on the fact that buspirone is inactive at 
muscarinic and histaminergic receptors where current 
55 agents known to be effective against motion sickness 
acts. Buspirone is also inactive at alpha-2 adrenoceptors 
where xylazine acts to induce emesis. Because buspi- 
rone blocks emesis elicited by both motion and chemi- 
cal stimuli, it has been found to be useful against an even 
60 broader spectrum of emetic agents including the cyto- 
toxic drug cisplatin (a cis-platinum compound) used in 
chemotherapy and is believed to be useful against gas- 
tric irritants such as copper sulfate. 
The other preferred compound used in the practice of 
65 the present invention is the naphthalene compound 
8-hydroxy-2(di-n-propylamino)-tetralin, sometimes re- 
ferred to as 8-OH-DPAT. 8-OH-DPAT has the follow- 
ing structural formula: 
5 
4,943,428 
5 (yH .HBr 
8-OH-DPAT is known to have antidepressant and 10 
h o l y t i c  effects on mammals. See, Kennett et al, “An- 
tidepressant-like Action of 5-HT1A Agonists and Con- 
ventional Antidepressants in an Animal Model of De- 
pression”, 134 Europ. J. Pharmacol. 265-274 (1987) and 
Tricklebank et al, “Mediation of the Discriminative 15 
Stimulus Properties of 8-hydroxy-2(di-n-propylamino)- 
tetralin (8-OH-DPAT) by the Putative-HT1A Recep- 
tor”, 133 Europ. J. Pharmacol. 47-56 (1987). As 8-OH- 
DPAT, l i e  buspirone, acts to stimulate serotonin-1A 
sites, applicants have found that the use of 8-OH-DPAT 20 
in accordance with the practice of the present invention 
blocks or otherwise alleviates both the symptoms of 
motion sickness as well as emesis induced by chemical 
agents. 
derstood, reference is made to the following examples, 
which are intended to illustrate the invention, but are 
not to be taken as limiting the scope thereof. 
EXAMPLE 1 
Twenty mature female cats with normal righting and 
post-rotational nystagmic reflexes but which were sus- 
ceptible to a well characterized motion stimulus were 
selected for testing. The basis for selection was that the 
cats vomited on at least one of the five screening tests. 35 
The screening tests were conducted on a motion 
stimulus device which resembles an amusement park 
Ferris wheel ride. The cats rode in clear plastic boxes 
suspended from 0.445 meter arms that were rotated at 
0.28 Hz. Motion tests were of 30 minutes duration fol- 40 
lowed by one minute of observation at rest. Further 
detail concerning the motion stimulus is reported by 
Crampton and Lucot,“A Stimulator for Laboratory 
Studies of Motion Sickness in Cats”, 56 Aviat. Space 
Environ. Med. 462-65(1985), the disclosure of which is 45 
hereby incorporated by reference. 
411 tests were separated by two weeks to prevent 
habituation to the motion stimulus. The dependent vari- 
able was retching, which was followed by vomiting in 
all cases. Freshly prepared buspirone hydrochloride 50 
was injected S.C. (subcutaneously) in a volume of 0.1 
d / k g  thirty minutes before exposure to the motion 
stimulus. All doses were of the base. Saline control tests 
were conducted before (Vl) and after (V2) determina- 
The administration of buspirone clearly blocked mo- 
tion sickness as shown by the results illustrated in FIG. 
1. The ED50 was 0.41 m a g  of body weight as com- 
puted by probit analysis. There was no significant 
change in the susceptibility of the cats during the course 60 
of the testing as shown by the incidence of retching on 
control tests before and after determination of the dose 
responsive curve. There was a correlation of 0.58 
(P<O.Ol) the minimum effective dose of buspirone 
against motion sickness and the susceptibility to motion 65 
sickness as measured by the percentage of tests during 
which retching occurred on the five previous screening 
tests. This indicates that the more susceptible the animal 
In order that the invention may be more readily un- 25 
30 
tion of the dose responsive curve. 55 
6 
is to motion sickness, the greater the premedication 
dosage required to suppress retching. 
EXAMPLE 2 
Buspirone was also found to be effective in blocking 
chemically induced emesis. In this test, fifteen female 
cats were used, none of which were included in the 
motion sickness tests reported above. The animals were 
injected S.C. with 0.66 mg/kg of xylazine base in a vol- 
ume of 0.066 ml/kg, placed in a clear plexiglass enclo- 
sure, and observed for 30 minutes or until the first retch. 
Seven days later, the cats received 4.0 mg/kg of body 
weight buspirone base S.C. thirty minutes before S.C. 
administration of 0.66 mg/kg of xylazine. Seven days 
thereafter, the cats received an S.C. administration of 
0.66 mg/kg of xylazine. 
As shown in Table I, the incidence of retching was 
reduced significantly by pretreating the cats with buspi- 
rone compared to the incidence on the pre- and post- 
xylazine challenges (one tail binomial test). The higher 
dosage levels of buspirone to block this chemically 
induced emesis is believed to be related to the more 
provocative stimulus of xylazine as an emetic agent as 
compared to motion as a stimulus. Following the ad- 
ministration of the higher doses of buspirone, the cats 
were more difficult to handle and exhibited strong de- 
fensive behavior. This behavior persisted to a lessening 
degree during handling and injections for several weeks 
thereafter. 
TABLE 1 
Effects of pretreatment with 4.0 mg/kg buspirone 
base on the incidence of retching induced by 0.66 m a g  
xylazine administered 30 min. later. 
No. retching/ 
Condition No. tested 
Pretest: 
xylazine alone 11/15 
Buspirone: 
then xylazine 5/15= 
Post-test: 
xylazine alone 14/156 
‘Significantly different from the pre- and post-tests by p <0.05 and p <O.M)Z 
respectively 
b o t  significantly different from the pre-test 
EXAMPLE 3 
A control and an experimental group were each as- 
signed six cats, four male and two female. Jugular cathe- 
ters were implanted unilaterally under ketamine and 
pentobarbital anesthesia and sterile conditions. Each 
catheter was implanted on the jugular, threaded under 
the skin and externalized through a stab wound in the 
back of the neck. Catheter patency was maintained by 
withdrawing blood, flushing with 50 U/ml heparin 
immediately following surgery and every other day 
thereafter. 
Experiments were conducted 72-96 hours after im- 
plantation. Cats in both experimental and control 
groups received intravenous infusions over a period of 
4-5 minutes of 7.5 mg/kg cisplatin (cis-platinum I1 di- 
amine dichloride from Sigma Chemical Co., St. Louis, 
Mo.). This dose has been established as the most reliable 
for eliciting emesis in the cat. See McCarthy and Bori- 
son, “Cisplatin-induced Vomiting Eliminated by Abla- 
tion of the Area Postrema in Cats”, Cancer Treat. Rep. 
68:401-404 (1984). 
7 
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8 
Buspirone (BusparR from Bristol-Myers Co., Evans- 8-OH-DPAT (Research Biochemicals Inc., Wayland, 
ville, Ind.) was administered subcutaneously to the cats Mass.) was dissolved in a sterile saline solution to an 
in the experimental group immediately before cisplatin injection volume of 0.01 d / k g  of body weight. The 
infusion. The dose was 4 mg/kg base and was dissolved order of doses was 0.04, 0.01, 0.002, and 0.02 mg/kg, 
in Sterile d i n e  in a concentration Of 4 mg/d.  The 5 respectively. The 8-OH-DpAT was administered sub- 
number and latency of emetic events (retching and cutaneously 15 minutes before the cat was exposed to 
vomiting) were recorded over the following six hours. the motion stimulus. 
The cats were euthanized by intravenous infusions of shown in FIG. 2, ~-OH-DPAT produced a dosage 
T-61 8 moechst* Somerville* N*J.) at the end Of the dependent decrease in the incidence of motion sickness 
observation period. 10 (solid circles) (Fisher-Yates test; P<O.Ol). There was 
Busphone was effective in preventing cisplatin- no change in the susceptibility of the cats as demon- 
induced emesis % shown by the strated by the absence of change in the pre- and post- 
vomited was lower than the number that were not pre- motion sick in both tests. The ED50 was 0.01 1 mg/kg of 
treated and vomited (Fisher's Exact Test; P<0'05)' The 15 body weight. The l i e  ofbest fit (dose responsive curve 
report in 
''* The number Of cats that received and drug vehicle tests in which eight of the ten cats became 
expressed as the log dose of the number of moles) was 
buspirone dose responsive curve in FIG. 1. 8-OH- 
DPAT was approximately 25 times more potent than 
Effects of buspirone on cisplatin-induced emesis B. Xylazine. Xylazine HCL (Bayvet, Shawnee, 
CONTROL Kans.) was dissolved in sterile saline solution to an 
Emetic Latency to Emetic Latency to injection volume of 0.066 ml/kg of body weight. The 
cat Events first Cat Events first compound was then administered subcutaneously, and 
488 1 72:45' 494 0 <3& 25 the cats were monitored for thirty minutes or for fifteen 
0 <3m minutes after the emetic event, whichever occurred 491 6 71:47 505 0 <3m 
500 0 >360 495 1 21417 later. Saline was administered before the xylazine chal- 
491 9 4751 499 0 <360 lenge both before and after determination of a dose 
421 6 9537 506 0 <360 3o responsive curve for the antiemetic compound 8-OH- 
'Minuta:Seconds DPAT to verify that xylazine was an effective emetic 
stimulus. 
In addition, saline solution alone was administered 
EXAMPLE 4 between determinations of dose responsive curves for 
free-fall 35 the antiemetic compounds to evaluate conditioned re- 
fighting and vestibulo-oc~ar reflexes but which were sponses to the injection procedure. Xylazine tests were 
susceptible to a motion stimulus conducted at weekly intervals. As in the motion chal- 
were for testing for both motion sickness and lenge, 8-OH-DPAT was dissolved in sterile saline soh- 
xylazine 8-OH-DPAT. ne basis for tion to an injection volume of 0.1 ml/kg. The order of 
tion was that the cats vomited on at least one of the five 40 doses was O*O19 0-04* O.l69 and Oh4 mg/kg* %OH- 
number of emetic events as well as the latency to the 
test; p<0.05). The cats sat quietly in the test cage dur- 
ing the observation and appeared normal. 
TABLE I1 
emesis were also si&lcantly different (wilcOxin's not different from parallel to the line describing the 
2o buspirone in alleviating motion sickness. 
BUSPIRONE 
489 2 171:35 517 
'No emuis during observation period 
Twenty mature female cats with 
=reefing tests. Another ten female cats which were not 
susceptible to motion sickness were selected and as- 
signed to the group of cats being tested in the xylazine 
challenge group. 
DPAT was administered s'Jbcutaneousb' 15 minutes 
before the administration of XYlazine. 
8-OH-DPAT also Produced a dose-dePendent de- 
crease in xylazine-induced emesis (Fisher-Yates test; 
Twenty-four male and female cats were selected and 45 P<o.o1) as illustrated by FIG. 2 (open circles). There 
assigned to the group of cats being tested in the cisplatin 
challenge. A few of the females were tested for motion 
sickness and found to be not susceptible; the male cats 
were not tested for susceptibility to motion sickness. In 
the control group were four males and six females. In 
the group receiving the low dose were three males and 
five females. In the group receiving the high dose were 
two males and four females. 
EMETIC CHALLENGES AND RESULTS 
A. Motion Stimulus. The screening tests were con- 
ducted on a motion stimulus device which resembles an 
amusement park Ferris wheel ride. The cats rode in 
clear plastic boxes suspended from 0.445 meter arms 
that were rotated at 0.28 Hz (17 rpm). Motion tests were 
minutes duration followed by one minute of observation 
at rest. Further detail concerning the motion stimulus is 
described in Example 1. 
411 tests were separated by two weeks to prevent 
habituation to the motion stimulus. The dependent vari- 
able was retching, which was followed by vomiting in 
all cases. Saline control tests were conducted before and 
after every determination of a dose responsive curve. 
.- - 
was no change in the efficacy of x&zine, with all ten 
cats vomiting to the administration of xylazine alone 
both before and after determination of the 8-OH-DPAT 
dose-responsive curve. The ED50 was 0.056 mg/kg of 
The dose-responsive curves for the effects of 8-OH- 
DPAT on motion sickness and xylazine-induced emesis 
were not different from parallel. When compared to the 
effects of buspirone on xylazine-induced emesis above, 
55 8-OH-DPAT was approximately 16 times more potent. 
The highest dose of 0.64 mg/kg produced strong defen- 
sive behavior in the cats similar to the behavior re- 
ported for buspirone above. However, unlike buspi- 
rone, the effect was not evident on the following day. 
C. Cisplatin. Jugular catheters were implanted under 
sterile conditions and ketamine and pentobarbital anes- 
thesia as in Example 3. Antibiotics were administered 
after the surgery. The catheters were implanted in the 
jugular vein, threaded under the skin, and externalized 
65 at the nape of the neck. Catheter patency was main- 
tained by withdrawing blood, flushing with 50 U/ml 
heparin and filling with lo00 U / d  heparin. This was 
done immediately after surgery and'every other day 
50 body weight. 
60 
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thereafter. The heparin was withdrawn just prior to the 
infusion of cisplatin. Experiments were conducted 
72-96 hours after implantation. 
Cisplatin (Sigma Chemical Co., St. Louis, Mo.) was 
prepared by placing it into a solution of 2 mg/ml in 
sterile water by gentle warming and sonicating. Both 
the experimental and control groups received intrave- 
nous infusions of cisplatin over a period of 4-5 minutes. 
The challenge dose of 7.5 mg/kg was chosen as in Ex- 
ample 3. 
In the experimental group, 8-OH-DPAT was admin- 
istered subcutaneously immediately before the cisplatin 
infusion. The dose of 0.16 m a g  was initially chosen 
because it produced acute and residual changes in be- 
havior, and its effects on xylazine-induced emesis were 
approximately equivalent to that of 4.0 mg/kg of buspi- 
rone. The number and latency of emetic events (retch- 
ing and vomiting) were observed for six hours after the 
infusion. At the end of the observation period, the cats 
were euthanized by intravenous administration of 
T-61 @ (Hoechst, Somerville, N.J.). 
As shown by Table 111, 8-OH-DPAT produced a 
decrease in cisplatin-induced emesis. The dose of 0.16 
mg/kg produced an increased latency to the fust emetic 
event that was not significant, and failed to alter sign& 
cantly the number of emetic events. The dose of 0.64 
mg/kg significantly decreased the number of events 
(P<0.05) and significantly altered the latency to the 
first event. Neither dose produced significant effects by 
5 
10 
15 
20 
25 
30 the Fisher-Yates test. As compared to the effects of 
buspirone on cisplatin-induced emesis, 8-OH-DPAT 
was approximately four times more potent. 
TABLE I11 
Control 0.16 rng/kg dose 0.64 rng/kg dose 35 
Iatencya/no.b latencyho. latencyho. 
47.85/9 61.35/12 49.15/1 
51.81/6 100.55/6 285.97/1 
71.78/6 102.67/5 360.00/0 
87.65/3 360.00/0 360.00/0 
95.62/6 360.00/0 360.00/0 
96.90/4 360.00/0 360.00/0 
171.58/2 360.00/0 360.00/0 
360.00/0 360.00/0 360.00/0 
‘Latency to the first emetic event in minutes; 360 denotes a test with no emesis. 
%umber of emetic events. 
72.75/1 171.83/3 360.00/0 40 
45 
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ten tested cats vomiting when xylazine was adminis- 
tered. 
With respect to motion sickness. Pretreatment with 
0.1 mg/kg of lorazepam decreased the number of cats 
becoming motion sick from eight to five, which was not 
considered significant by either McNemar’s test or by 
Wilcoxin’s test as applied to the latency to emesis. 
Higher doses were not tested because the cats were 
drowsy and ataxic at this dose. Observations during 
xylazine testing using a dose of 0.4 mg/kg lorazepam 
established that the higher dose produced pronounced 
ataxia and gross nonspecific behavior observable even 
the following day. These effects were considered toxic, 
and the motion group of cats was not subjected to the 
higher lorazepam dosage level. 
The results show that the nonspecific factors associ- 
ated with relief from anxiety do not account for the 
antiemetic effects observed. Doses of lorazepam suffi- 
cient to produce pronounced nonspecific effects in the 
cats tested still did not affect the response to both mo- 
tion-induced and xylazine-induced emesis. 
While certain representative embodiments and details 
have been shown for purposes of illustrating the inven- 
tion, it will be apparent to those skilled in the art that 
various changes in the methods and apparatus disclosed 
herein may be made without departing from the scope 
of the invention, which is defined in the appended 
claims. 
What is claimed is: 
1. A method for the alleviation of motion sickness, 
which comprises administering a nontoxic, therapeuti- 
cally effective dose of 8-hydroxy-2(di-n-propylamino)- 
tetralin to a mammal in need of such treatment. 
2. The method of claim 1 in which the dosage of 
8-hydroxy-2(di-n propy1amino)-tetralin is from about 
0.002 to about 0.64 mg/kg of body weight. 
3. The method of claim 1 in which the dosage of 
8-hydroxy-2(di-n-propylamino)-tetraliin is about 0.01 1 
mg/kg of body weight. 
4. A method for the alleviation of chemically induced 
emesis which comprises administering a nontoxic, ther- 
apeutically effective dose of 8-hydroxy-2(di-n- 
propy1amino)-tetralin to a mammal in need of such 
treatment. 
5. The method of claim 4 in which the emesis was 
induced by a cis-platin compound. 
6. The method of claim 5 in which the dosage of 
8-hvdroxy-2(di-n-~ro~vl~o~-tetralin is from about 
The cats tested in Example 4 above were also tested 50 0. l i  to about 0.64.. m a g  of body weight. 
for the possibility that the known anti-anxiety effects of 7. The method of claim 4 in which the emesis was 
both buspirone and 8-OH-DPAT could be responsible induced by xylazine. 
for the antiemetic effects which were observed. Known 8. The method of claim 7 in which the dosage of 
antianxiety agents such as barbiturates have been re- 8-hydroxy-2(di-n-propylamino)-tetralin is from about 
ported to alleviate motion sickness in dogs, while ben- 55 0.01 to about 0.64 mg/kg of body weight. 
zodiazepines have been reported to alleviate the emesis 9. The method of claim 7 in which the dosage of 
associated with cancer chemotherapy in humans. 8-hydroxy-2(di-n-propylamino)-tetralin is about 0.056 
With respect to xylazine-induced emesis, lorazepam mg/kg. 
(Sigma Chemical Co., St. Louis, Mo.), a benzodiazepine 10. A method for the alleviation of motion sickness 
compound having known anti-anxiety and sedative 60 which comprises administering a nontoxic, therapeuti- 
effects, failed to have any effect even though lorazepam cally effective dose of a composition which stimulates 
has been reported to alleviate emesis in humans induced serotonin-1A receptors in a mammal in need of such 
by cancer chemotherapy. The lorazepam was prepared treatment. 
by suspending it in sterile saline solution with one drop 11. A method for the alleviation of chemically in- 
of Tween-80 per five ml by sonication in hot water. The 65 duced emesis which comprises administering a non- 
PH was adjusted to 7.0 with sodium hydroxide. The toxic, therapeutically effective dose of a composition 
injection volume was 0.5 ml/kg. pretreatment with which stimulates serotonin-1A receptors in a mammal 
doses of 0.1 and 0.4 mg/kg of lorazepam resulted in all in need of such treatment. 
12 
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12- A method for the alleviation of emesis induced by 
copper sulfate which comprises administering a non- 
toxic, therapeutically effective dose of 8-hydroxy-2(di- 
n - p r o p y l ~ o ) - t e t r ~ ~  to a mammal in need of such 
treatment. 
the chemical agents cis-platin compounds, xylazine, and 
toxic, therapeutically effective dose of a composition 
which stimulates serotonin-1A receptors in a mammal 
in need of such treatment. 
the Chemical agents Cis-Platin compounds, XYlWine, and copper sulfate which comprises administering a non- 
13. A method for the alleviation of emesis induced by * * * * *  
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